Implications of dysregulated endogenous cannabinoid family members in the pathophysiology of endometriosis
Observational studyHumansOther animals
- Design
- Observational study
- Subjects
- Patients with endometriosis and healthy fertile controls (numbers not stated in the abstract); a mouse model of endometriosis
- Dose used in the study
- Not stated in the abstract; no treatment was given
- Duration
- Not stated in the abstract
- What was measured
- Mass spectrometry of endocannabinoids in plasma, endometriosis lesions and endometrium; gene expression and immunohistochemistry of CB1 and CB2 receptors.
What the authors reported
Plasma endocannabinoids did not differ between patients and controls, but palmitoylethanolamide was significantly higher in endometriosis lesions than in patients' own endometrium, while CB2 receptor expression was lower in lesions. In mice with endometriosis, PEA was higher in plasma and lesions than in sham controls.
Limits of this study
A tissue measurement study in people and mice; it did not test palmitoylethanolamide as a treatment and cannot show effect in people treated in practice. Sample sizes are not given in the abstract. Funding and conflicts not stated in the abstract.
Source
PubMed 35559864 · doi:10.1016/j.xfss.2021.09.005
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.